A metabolomic study using HPLC-TOF/MS coupled with ingenuity pathway analysis: Intervention effects of Rhizoma Alismatis on spontaneous hypertensive rats

Journal of Pharmaceutical and Biomedical Analysis

Volumn 117, Issue , 2016, Pages 446-452

  Chu, Yanjun ^a,b   Jiang, Haiqiang ^b   Ju, Jianqing ^b   Li, Yunlun ^a,b   Gong, Lili ^b   Wang, Xiaoming ^b   Yang, Wenqing ^b   Deng, Yue ^b  

^a AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

High performance liquid chromatography coupled with time of flight mass spectrometry; Hypertension; Metabolomics; Rhizoma Alismatis; Traditional Chinese medicine

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; GLYCEROPHOSPHOLIPID; PLANT EXTRACT; PURINE; RHIZOMA ALISMATIS EXTRACT; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG EFFECT; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; INGENUITY PATHWAY ANALYSIS; MALE; METABOLOMICS; MULTIVARIATE ANALYSIS; NONHUMAN; PARTIAL LEAST SQUARES REGRESSION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PURINE METABOLISM; RAT; RHIZOMA ALISMATIS; SERUM; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TIME OF FLIGHT MASS SPECTROMETRY; UNIVARIATE ANALYSIS; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; RHIZOME; TANDEM MASS SPECTROMETRY; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUGS, CHINESE HERBAL; MALE; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, INBRED SHR; RATS, WISTAR; RHIZOME; TANDEM MASS SPECTROMETRY;

EID: 84943621062     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.09.026     Document Type: Article

References (26)

1. Weber M.A., Schiffrin E.L., White W.B., Mann S., Lindholm L.H., Kenerson J.G., Flack J.M., Carter B.L., Materson B.J., Ram C.V., Cohen D.L., Cadet J.C., Jean-Charles R.R., Taler S., Kountz D., Townsend R., Chalmers J., Ramirez A.J., Bakris G.L., Wang J., Schutte A.E., Bisognano J.D., Touyz R.M., Sica D., Harrap S.B. Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the international society of sypertension. J. Hypertens. 2014, 32:3-15.
2. Jones D.W., Hall J.E. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure and evidence from new hypertension trials. Hypertension 2004, 43:1-3.
3. Lu X.Y., Shi Z.X. Key points in treating hypertension by integrative medicine. Chin. J. Integr. Tradit. West. Med. 2011, 31:1561-1564.
4. Makino B., Kobayashi M., Kimura K., Ishimatsu M., Sakakibara I., Higuchi M., Kubo M., Sasaki H., Okada M. Local variation in the content of angiotensin II and arginine vasopressin receptor antagonistic terpenoids in the rhizomes of Alisma orientale. Planta Med. 2002, 68:226-231.
5. Feng Y.L., Chen H., Tian T., Chen D.Q., Zhao Y.Y., Lin R.C. Diuretic and anti-diuretic activities of the ethanol and aqueous extracts of Alismatis rhizome. J. Ethnopharmacol. 2014, 154:386-390.
6. Dan H., Wu J., Peng M., Hu X., Song C., Zhou Z., Yu S., Fang N. Hypolipidemic effects of Alismatis rhizome on lipid profile in mice fed high-fat diet. Saudi Med. J. 2011, 32:701-707.
7. Li Q., Qu H. Study on the hypoglycemic activities and metabolism of alcohol extract of Alismatis rhizoma. Fitoterapia 2012, 83:1046-1053.
8. Gu Y., Lu C., Zha Q., Kong H., Lu X., Lu A., Xu G. Plasma metabonomics study of rheumatoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry. Mol. Biosyst. 2012, 8:1535-1543.
9. Nicholson J.K., Lindon J.C. Systems biology: metabonomics. Nature 2008, 455:1054-1056.
10. Kordalewska M., Markuszewski M.J. Metabolomics in cardiovascular diseases. J. Pharm. Biomed. Anal. 2015, 10.1016/j.jpba.2015.04.021.
11. Yang B., Zhang A., Sun H., Dong W., Yan G., Li T., Wang X. Metabolomic study of insomnia and intervention effects of Suanzaoren decoction using ultra-performance liquid-chromatography/electrospray-ionization synapt high-definition mass spectrometry. J. Pharm. Biomed. Anal. 2012, 58:113-124.
12. Liu Y.T., Peng J.B., Jia H.M., Cai D.Y., Zhang H.W., Yu C.Y., Zou Z.M. UPLC-Q/TOF MS standardized Chinese formula Xin-Ke-Shu for the treatment of atherosclerosis in a rabbit model. Phytomedicine 2014, 21:1364-1372.
13. Jiang H., Shen Z., Chu Y., Li Y., Li J., Wang X., Yang W., Zhang X., Ju J., Xu J., Yang C. Serum metabolomics research of the anti-hypertensive effects of Tengfu Jiangya tablet on spontaneously hypertensive rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2015, 1002:210-217.
14. Chong I.G., Jun C.H. Performance of some variable selection methods when multicollinearity is present. Chemom. Intell. Lab. Syst. 2005, 78:103-112.
15. Kutzing M.K., Firestein B.L. Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther. 2008, 324:1-7.
16. Grayson P.C., Kim S.Y., LaValley M., Choi H.K. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 2011, 63:102-110.
17. Wang J., Qin T., Chen J., Li Y., Wang L., Huang H., Li J. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One 2014, 9:e114259.
18. Feig D.I. Hyperuricemia and hypertension. Adv. Chronic Kidney Dis. 2012, 19:377-385.
19. Parthasarathy S., Barnett J. Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:9741-9745.
20. Kistler T., Kistler B. Correlation between disorders of lipid metabolism and hypertension in 10,892 participants in the Heureka Study. Schweiz Rundsch Med. Prax 1993, 82:1222-1233.
21. Lopes H.F., Silva H.B., Soares J.A., Filho B., Consolim-Colombo F.M., Giorgi D.M., Krieger E.M. Lipid metabolism alterations in normotensive subjects with positive family history of hypertension. Hypertension 1997, 30:629-631.
22. Takahashi M., Okazaki H., Ogata Y., Takeuchi K., Ikeda U., Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002, 161:387-394.
23. Rikitake Y., Kawashima S., Yamashita T., Ueyama T., Ishido S., Hotta H., Hirata K., Yokoyama M. Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1006-1012.
24. Kume N., Gimbrone M.J. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin. Invest. 1994, 93:907-911.
25. 2+ signals and inhibit the phosphorylation of endothelial NO synthase and cytosolic phospholipase A2. Biochem. J. 2004, 380:533-539.
26. Davda R.K., Stepniakowski K.T., Lu G., Ullian M.E., Goodfriend T.L., Egan B.M. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension 1995, 26:764-770.